01877 Shanghai Junshi Biosciences (H)

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints
EN
08/10/2020

Underlying

01877Shanghai Junshi Biosciences (H)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shanghai Junshi Biosciences (H)

 PRESS RELEASE
Free
01877 Shanghai Junshi...

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment...

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%.Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC.The final OS analysis of JUPITER-06 confirms the...

December 6, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL...

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug application (“NDA”) for the company’s product, roconkibart injection (a recombinant humanized anti-IL-17A monoclonal antibody injection, product code: JS005), for the tr...

December 5, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase ...

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous i...

November 25, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces FDA’s Approval of IND Application for Pha...

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, ...

October 17, 2025 1 EN
 PRESS RELEASE
Free
01877 Shanghai Junshi...

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for t...

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel...

September 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch